Glucagon-Like Peptide-2 · Teduglutide · Gattex
Intestinal growth peptide — short bowel syndrome and gut repair.
FDA
Approved
WADA
Not Listed
HALF-LIFE
~7 hours (native), ~2 days (Teduglutide)
ROUTE
SubQ injection
SCHEDULE
Daily
In Plain English
Intestinal growth peptide — short bowel syndrome and gut repair.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
ApprovedFDA approved for human use.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
SubQ injectionAdministration via subq injection.
Short bowel syndrome
Gut mucosal repair
Crohn's disease
Intestinal absorption
GLP-2 is an intestinal growth factor produced by L-cells in the gut that promotes intestinal epithelial cell proliferation and reduces apoptosis. Teduglutide (Gattex) is the FDA-approved modified analog with a longer half-life. It's used medically for short bowel syndrome and has research applications in gut repair protocols.
Abdominal pain
Nausea
Fluid retention
Injection site reactions
Rare: intestinal obstruction
Using native GLP-2 when Teduglutide (the longer half-life analog) is available and appropriate
Not dose-adjusting by body weight — GLP-2 is one of the few research peptides with weight-based dosing protocols
Expecting gut results without adequate nutrition — intestinal epithelial repair requires sufficient dietary protein and micronutrients
BPC-157 — synergistic gut repair combination; generally beneficial
Corticosteroids — may reduce the mucosal growth signaling that GLP-2 drives
Octreotide — can reduce endogenous GLP-2 activity when co-administered; avoid combination
GLP-2 is a gut repair peptide that works at the cellular proliferation level — stimulating intestinal villus growth and mucosal restoration. Most valuable for serious conditions like SBS or post-surgical gut rehabilitation. For general gut health, BPC-157 and KPV are more accessible and nearly as effective for most users.
Stats
Sources & Studies
Drucker DJ. et al., Annu Rev Physiol, 2002